Literature DB >> 28567587

Estimating the annual frequency of synchronous brain metastasis in the United States 2010-2013: a population-based study.

Courtney Kromer1, Jordan Xu2, Quinn T Ostrom3,4, Haley Gittleman3,4, Carol Kruchko4, Raymond Sawaya5, Jill S Barnholtz-Sloan6,7.   

Abstract

Brain metastases (BM) are one of the most common types of brain tumors and are a relatively common event in the disease process for several high-incidence cancer types, including breast and lung cancers. Historically, information on metastases including BM have not been collected as part of national cancer registration in the US, but BM at time of primary cancer diagnosis (SBM), is now collected by the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) system. Using data from 18 SEER registries from 2010 to 2013, we assessed the frequency of SBM at time of primary diagnosis in the US by site, histology group, sex, race, age, and insurance status. There were 1,634,954 total primary cancer cases in SEER from 2010 to 2013, 1.7% of which presented with SBM. The cancer type with the highest proportion of SBM was lung cancer (10.8% of cases with SBM), followed by esophageal (1.5%), kidney (1.4%), and melanoma (1.2%). SBM varied by age, sex, race, and insurance status for most histologies. Our results reflect the high proportion of patients who are diagnosed with lung cancer at late stages and present with SBM, in contrast to other common cancers in the US where SBM is less common. Demographic variation in molecular subtype and risk behavior may influence variation in SBM. BM is a relatively common event in late stage cancer and cause significant morbidity and mortality, and assessment of accurate population-based data is critical to estimate total disease burden.

Entities:  

Keywords:  Cancer registries; Lung cancer; Metastatic brain tumors; SEER

Mesh:

Year:  2017        PMID: 28567587     DOI: 10.1007/s11060-017-2516-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  Epidemiology of brain metastases.

Authors:  Lakshmi Nayak; Eudocia Quant Lee; Patrick Y Wen
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

2.  EGFR mutation and brain metastasis in pulmonary adenocarcinomas.

Authors:  Dong-Yeop Shin; Im Il Na; Cheol Hyeon Kim; Sunhoo Park; HeeJong Baek; Sung Hyun Yang
Journal:  J Thorac Oncol       Date:  2014-02       Impact factor: 15.609

Review 3.  Brain metastases: epidemiology and pathophysiology.

Authors:  Igor T Gavrilovic; Jerome B Posner
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

Review 4.  Therapeutic management of brain metastasis.

Authors:  Evert C A Kaal; Charles G J H Niël; Charles J Vecht
Journal:  Lancet Neurol       Date:  2005-05       Impact factor: 44.182

5.  Female sex and oral contraceptive use accelerate nicotine metabolism.

Authors:  Neal L Benowitz; Christina N Lessov-Schlaggar; Gary E Swan; Peyton Jacob
Journal:  Clin Pharmacol Ther       Date:  2006-05       Impact factor: 6.875

6.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.

Authors:  Jill S Barnholtz-Sloan; Andrew E Sloan; Faith G Davis; Fawn D Vigneau; Ping Lai; Raymond E Sawaya
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

Review 7.  Cancer disparities by race/ethnicity and socioeconomic status.

Authors:  Elizabeth Ward; Ahmedin Jemal; Vilma Cokkinides; Gopal K Singh; Cheryll Cardinez; Asma Ghafoor; Michael Thun
Journal:  CA Cancer J Clin       Date:  2004 Mar-Apr       Impact factor: 508.702

8.  Association of health insurance with outcomes in adults ages 18 to 64 years with melanoma in the United States.

Authors:  Arya Amini; Chad G Rusthoven; Timothy V Waxweiler; Bernard L Jones; Christine M Fisher; Sana D Karam; David Raben
Journal:  J Am Acad Dermatol       Date:  2015-12-06       Impact factor: 11.527

9.  Epidemiology of brain tumors: the national survey of intracranial neoplasms.

Authors:  A E Walker; M Robins; F D Weinfeld
Journal:  Neurology       Date:  1985-02       Impact factor: 9.910

10.  Lung cancer trends: smoking, obesity, and sex assessed in the Staten Island University's lung cancer patients.

Authors:  Shilpi Gupta; Samer Hassan; Vijaya R Bhatt; Houssein Abdul Sater; Asma Dilawari
Journal:  Int J Gen Med       Date:  2014-07-02
View more
  18 in total

1.  Mixture Model Segmentation System for Parasagittal Meningioma brain Tumor Classification based on Hybrid Feature Vector.

Authors:  L Arokia Jesu Prabhu; A Jayachandran
Journal:  J Med Syst       Date:  2018-11-03       Impact factor: 4.460

2.  Disparities in the use of stereotactic radiosurgery for the treatment of lung cancer brain metastases: a SEER-Medicare study.

Authors:  Mustafa S Ascha; Kaitlyn Funk; Andrew E Sloan; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Clin Exp Metastasis       Date:  2019-11-08       Impact factor: 5.150

Review 3.  Imaging of intranasal drug delivery to the brain.

Authors:  Michael C Veronesi; Mosa Alhamami; Shelby B Miedema; Yeonhee Yun; Miguel Ruiz-Cardozo; Michael W Vannier
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-02-25

4.  Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma.

Authors:  Lauren E Haydu; Serigne N Lo; Jennifer L McQuade; Rodabe N Amaria; Jennifer Wargo; Merrick I Ross; Janice N Cormier; Anthony Lucci; Jeffrey E Lee; Sherise D Ferguson; Robyn P M Saw; Andrew J Spillane; Kerwin F Shannon; Jonathan R Stretch; Patrick Hwu; Sapna P Patel; Adi Diab; Michael K K Wong; Isabella C Glitza Oliva; Hussein Tawbi; Matteo S Carlino; Alexander M Menzies; Georgina V Long; Alexander J Lazar; Michael T Tetzlaff; Richard A Scolyer; Jeffrey E Gershenwald; John F Thompson; Michael A Davies
Journal:  J Clin Oncol       Date:  2020-01-28       Impact factor: 44.544

5.  Patterns of recurrence after intracranial stereotactic radiosurgery for brain-only metastases from non-small cell lung cancer and the impact of upfront thoracic therapy with synchronous presentation.

Authors:  Derek P Bergsma; Michael J Moravan; Jaipreet S Suri; Michael A Cummings; Kenneth Y Usuki; Deepinder P Singh; Michael T Milano
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

Review 6.  Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.

Authors:  Minjee Kim; Sani H Kizilbash; Janice K Laramy; Gautham Gampa; Karen E Parrish; Jann N Sarkaria; William F Elmquist
Journal:  Pharm Res       Date:  2018-07-12       Impact factor: 4.200

Review 7.  Novel Systemic Treatments for Brain Metastases From Lung Cancer.

Authors:  Bicky Thapa; Adam Lauko; Kunal Desai; Vyshak Alva Venur; Manmeet S Ahluwalia
Journal:  Curr Treat Options Neurol       Date:  2018-09-27       Impact factor: 3.598

Review 8.  From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC.

Authors:  Maria Protopapa; Vassilis Kouloulias; Styliani Nikoloudi; Christos Papadimitriou; Giannis Gogalis; Anna Zygogianni
Journal:  J Oncol       Date:  2019-02-03       Impact factor: 4.375

9.  Presence of Brain Metastases at Initial Diagnosis of Cancer: Patient Characteristics and Outcome.

Authors:  Carsten Nieder; Ellinor Haukland; Bård Mannsåker; Adam R Pawinski; Rosalba Yobuta; Astrid Dalhaug
Journal:  Cureus       Date:  2019-02-21

Review 10.  Management of brain metastases according to molecular subtypes.

Authors:  Riccardo Soffietti; Manmeet Ahluwalia; Nancy Lin; Roberta Rudà
Journal:  Nat Rev Neurol       Date:  2020-09-01       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.